CC
CRDF icon

Commodore Capital’s Cardiff Oncology CRDF Stock Holding History

Commodore Capital’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,384,616
Closed -$16.9M – 35
2025
Q1 		$16.9M Hold
5,384,616
– – 1.25% 21
2024
Q4 		$23.4M Buy
+5,384,616
New +$16.8M 1.71% 18

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital's CRDF Position: Q2 2025 in Review

Commodore Capital sold out of Cardiff Oncology (CRDF) in Q2 2025, closing a stake of 5,384,616 shares — an estimated $16.9M sold.

Commodore Capital first reported a position in CRDF in Q4 2024 and held it in 2 quarters. The position peaked at $23.4M in Q4 2024. 114 funds tracked by Wall St. Rank hold CRDF as of Q2 2025.

  • Commodore Capital reported no remaining Cardiff Oncology position as of Q2 2025 after selling out during the quarter.
  • Commodore Capital sold 5,384,616 Cardiff Oncology shares in Q2 2025, an estimated $16.9M.
  • Commodore Capital first reported a position in Cardiff Oncology in Q4 2024 and held it in 2 quarters.
  • Commodore Capital's Cardiff Oncology position peaked at $23.4M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2025.

Based on Commodore Capital's 13F filing for Q2 2025, filed 14 Aug 2025.